New York, November 2026 – Julie Gerardi joins Standard Model Biomedicine from Bioptimus, where she served as Chief Commercial Officer, leading strategic partnerships with pharmaceutical and research organizations and driving go-to-market strategy for a universal AI foundation model for biology. A biochemist by training with more than 25 years of experience across early-stage startups and Fortune 500 organizations, she brings a rare combination of scientific grounding and commercial execution to the role.
Prior to Bioptimus, Julie served as Vice President of Business Development and Strategy at Parse Biosciences, where she led commercial strategy for large-scale single-cell sequencing applications in drug discovery and development. Earlier, as Vice President of Business Development at Tempus, she built out the company’s biological modeling and tumor organoid business unit.
Standard Model Biomedicine is developing a JEPA World Model that functions as a multidimensional biological reasoning engine, predicting with causal inference and counterfactual modeling how a patient’s disease will progress over time and how they will respond to any therapy. As the company moves from development into implementation, Julie’s appointment positions it to translate that science into durable commercial partnerships.
The search was led by Nick Mahoney at Metric.
Kevin Brown, Co-Founder and CEO, Standard Model Biomedicine commented, “Julie has spent her career at the point where cutting-edge biology and AI meet the realities of drug development, from single-cell sequencing to tumor modeling to foundation models. As Standard Model Biomedicine moves from development to implementation, her experience and relationships are exactly what we need. She knows how to turn novel science into partnerships that last.”
Julie Gerardi, SVP and Head of Business Development and Strategy, Standard Model Biomedicine commented: “Standard Model’s ability to simulate patient trajectories with causality in latent space will accelerate how drugs are developed and how clinical trials are designed. I am excited to build with this talented team of AI-native pharma expats at the intersection of AI, drug development, and big data.”
Nick Mahoney, Director, Metric, commented: “Placing a leader of Julie’s caliber into a platform like Standard Model Biomedicine is exactly the kind of mandate Metric Bio was built for. The intersection of AI and drug development is one of the most competitive talent markets in the life sciences right now, and finding someone with Julie’s breadth of experience across commercial strategy, scientific partnerships, and business development at this level takes genuine market depth. This is a hire that will shape the trajectory of the business.”
About Metric
Metric is a New York-founded executive and specialty search firm, recognized by the Financial Times as one of the fastest growing companies. Partnering with some of the world’s most innovative businesses, Metric builds high-performing global teams across Life Sciences, Infrastructure, Engineering, and Data Centers.
Through Metric Exec, the firm delivers C-suite and board-level appointments across its sectors, from high growth businesses to investor-backed portfolios. Metric is backed by Southfield Capital and operates from seven offices across the US and UK.
